BPG is committed to discovery and dissemination of knowledge
Featured Articles
12/5/2025 11:30:28 AM | Browse: 36 | Download: 75
 |
Received |
|
2025-06-17 01:53 |
|
Peer-Review Started |
|
2025-06-17 01:54 |
|
First Decision by Editorial Office Director |
|
2025-06-22 10:44 |
|
Return for Revision |
|
2025-06-22 10:44 |
|
Revised |
|
2025-06-24 02:33 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-09-24 02:43 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-09-24 07:14 |
|
Articles in Press |
|
2025-09-24 07:14 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-11-19 09:35 |
|
Publish the Manuscript Online |
|
2025-12-05 11:28 |
| ISSN |
2150-5349 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Quick glance at 'metabolic dysfunction associated steatotic liver disease' therapeutics: Targets, trials, and trends
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
George S Zacharia, Muhammad H Ashraf, Franklin Sosa, Anu Jacob and Harish Patel |
| Funding Agency and Grant Number |
|
| Corresponding Author |
George S Zacharia, Academic Fellow, DM, MD, Department of Internal Medicine, Bronx Care Health System, 1650 Grand Concourse, Bronx, NY 10457, United States. george.lenx@yahoo.com |
| Key Words |
Metabolic dysfunction-associated steatotic liver disease; Metabolic dysfunction-associated steatohepatitis; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Resmetirom; Fatty liver; Vitamin E; Insulin resistance; Obeticholic acid |
| Core Tip |
Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), have emerged as leading causes of chronic liver disease globally, paralleling the rise in obesity, type 2 diabetes, and metabolic syndrome. These conditions significantly increase the risk of cirrhosis, and hepatocellular carcinoma, creating an urgent need for effective treatment strategies. Recent advances in pharmacotherapy, including agents targeting metabolic pathways, inflammation, and fibrosis offer promising and novel therapeutic landscapes. Early recognition and intervention are essential to prevent disease progression and reduce the growing global burden of MASLD/MASH. |
| Publish Date |
2025-12-05 11:28 |
| Citation |
Zacharia GS, Ashraf MH, Sosa F, Jacob A, Patel H. Quick glance at 'metabolic dysfunction associated steatotic liver disease' therapeutics: Targets, trials, and trends. World J Gastrointest Pharmacol Ther 2025; 16(4): 110827 |
| URL |
https://www.wjgnet.com/2150-5349/full/v16/i4/110827.htm |
| DOI |
https://dx.doi.org/10.4292/wjgpt.v16.i4.110827 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
